What's Happening?
A recent study published in Scientific Reports has found that commonly prescribed cardiovascular medications, such as statins, diuretics, and blood pressure drugs, do not negatively impact survival rates among patients with multiple myeloma. This international
research involved collaboration among scientists and oncologists from the United States, Australia, Qatar, and the United Arab Emirates. The study analyzed data from three major Phase III clinical trials (MAIA, POLLUX, and CASTOR) involving 1,804 patients. The researchers assessed whether patients taking cardiovascular drugs at the start of their myeloma treatment experienced differences in progression-free survival, overall survival, or serious adverse events. The findings suggest that most cardiovascular medications do not worsen survival outcomes, although ACE inhibitors and ARBs were associated with longer progression-free survival but also higher odds of severe adverse events.
Why It's Important?
The study's findings are significant as they provide reassurance to both clinicians and patients that common cardiovascular medications can be safely continued during myeloma treatment without adversely affecting survival outcomes. This is particularly important for older adults, who are more likely to have multiple health conditions requiring such medications. The research highlights the need for systematic collection and analysis of concomitant medications in oncology trials to better anticipate adverse events and tailor supportive care. The study also emphasizes the importance of monitoring kidney function and metabolic parameters in patients on ACE inhibitors or ARBs, especially those who are older or more vulnerable.
What's Next?
The researchers plan to expand their study to evaluate the effects of drug dosage, duration, adherence, and interactions with specific myeloma regimens. This will help develop practical risk-stratification approaches to identify which patients can safely continue cardiovascular drugs and who may require closer monitoring. The study underscores the need for more comprehensive data collection in oncology trials to improve patient safety and treatment outcomes. Clinicians are encouraged to use these findings to inform their practice and provide evidence-based answers to patients concerned about the interaction between their heart medications and cancer treatment.
